Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jun 26;10(1):10445.
doi: 10.1038/s41598-020-67318-6.

Gabapentin-induced drug-seeking-like behavior: a potential role for the dopaminergic system

Affiliations

Gabapentin-induced drug-seeking-like behavior: a potential role for the dopaminergic system

Yusuf S Althobaiti et al. Sci Rep. .

Abstract

Drugs of abuse represent a growing public health crisis. Accumulating evidence indicates that gabapentin (GBP), a prescription drug, is prone to misuse, abuse, withdrawal, and dependence. Commonly, drugs of abuse modulate the dopaminergic system to induce addiction. In this study, we used the conditioned place preference (CPP) model to investigate the involvement of the dopamine 1 (D1) receptor on the reward and reinforcement behavior of GBP. Under a CPP paradigm, male BALB/c mice were intraperitoneally injected either saline or 100, 200, or 300 mg/kg of GBP and confined to the injection-paired chamber for 30 min. In the pre-conditioning phase, mice were conditioned for 3 days, and baseline data were collected. In the conditioning phase, mice were given once-daily alternating injections of either GBP or saline for 8 days and subsequently assessed in a post-conditioning test. Injections of 300 mg/kg of GBP significantly increased the time spent in the drug-paired chamber compared to the saline-paired chamber. However, lower doses of GBP (100 and 200 mg/kg) showed no effect. Pre-treatment with SKF-83566, a D1 receptor antagonist, attenuated GBP-induced CPP. Thus, for the first time, we show that GBP can induce CPP through a dopaminergic-dependent mechanism.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Figure 1
Figure 1
Time spent in conditioning chambers during phases of pre-test and post-test in the groups of the experiment 1: the control (A), GBP 100 (B), GBP 200 (C), and GBP 300 (D) group. No significant changes in time spent were found in chambers during all tested phases in the control, GBP 100 and GBP 200 groups. In GBP 300 group, a significant increase in time spent in GBP-paired chamber as compared to the Saline-paired chamber was found. *p < 0.05. Values shown as means ± S.E.M. N = 7–9/group.
Figure 2
Figure 2
Time spent in conditioning chambers during phases of pre-test and post-test in the groups of the experiment 2: the saline-saline (A), SKF-S (B), S-GBP (C), and SKF-GBP (D) group. No significant changes in time spent were found in chambers during all tested phases in the Saline-Saline and SKF-S groups. In the S-GBP group, a significant increase in time spent in the GBP-paired chamber as compared to the saline-paired chamber was found. SKF pretreatment blocked the GBP-induced increase in time spent. **p < 0.01. Values shown as means ± S.E.M. N = 6–8/group.
Figure 3
Figure 3
Experimental schedule of the CPP.

References

    1. Ibrahim Y, Hussain SM, Alnasser S, Almohandes H, Sarhandi I. Patterns and sociodemographic characteristics of substance abuse in Al Qassim, Saudi Arabia: a retrospective study at a psychiatric rehabilitation center. Ann. Saudi Med. 2018;38:319–325. doi: 10.5144/0256-4947.2018.319. - DOI - PMC - PubMed
    1. Evoy KE, Covvey JR, Peckham AM, Ochs L, Hultgren KE. Reports of gabapentin and pregabalin abuse, misuse, dependence, or overdose: An analysis of the Food And Drug Administration Adverse Events Reporting System (FAERS) Res. Soc. Adm. Pharm. 2019;15:953–958. doi: 10.1016/j.sapharm.2018.06.018. - DOI - PubMed
    1. Driot D, Jouanjus E, Oustric S, Dupouy J, Lapeyre-Mestre M. Patterns of gabapentin and pregabalin use and misuse: results of a population-based cohort study in France. Br. J. Clin. Pharmacol. 2019;85:1260–1269. doi: 10.1111/bcp.13892. - DOI - PMC - PubMed
    1. Panebianco M, Al-Bachari S, Weston J, Hutton JL, Marson AG. Gabapentin add-on treatment for drug-resistant focal epilepsy. Cochrane Database Syst. Rev. 2018;10:CD00415. doi: 10.1002/14651858.CD001415.pub3. - DOI - PMC - PubMed
    1. Moore A, Derry S, Wiffen P. Gabapentin for chronic neuropathic pain. JAMA. 2018;319:818–819. doi: 10.1001/jama.2017.21547. - DOI - PubMed

Publication types